Compare Enveric Biosciences Inc (ENVB) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Oscar Health Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Oscar Health Inc trades at $33.05 (market cap $10.16B). The key difference: Oscar Health Inc is far larger — about 1518.7× Enveric Biosciences Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Oscar Health Inc for 15 Days on average.
| ENVB | OSCR | |
|---|---|---|
Market Cap | $6.69M | $10.16B |
Volume | 41,141 | 5,418,697 |
Sector | Health | Health |
52-Week High | $10.80 | $33.81 |
52-Week Low | $1.27 | $10.85 |
Typical Hold Time | 14 Days | 15 Days |
Enterprise Value | -$1.60M | $6.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Oscar Health (OSCR) trades at $32.91, up 1.76% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, with profitability turning positive at $551M net income. Recent earnings beats and raised guidance have driven positive sentiment, though the stock faces challenges from rising medical costs and competitive pressures in the ACA market.
The outlook remains constructive with analyst consensus at $34.00 and strong institutional interest, though investors should monitor execution risks and medical cost trends. The combination of market share gains, margin expansion potential, and bullish technical setup supports further upside if the company can maintain its growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
